ClinicalTrials.gg
RecruitingNCT07455526FITTUpdated Oct 15, 2026

Facilitation to Increase Tobacco Treatment

An interventional study of Multi-component facilitation in Serious Mental Illness and Tobacco Use Disorder, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Tobacco Use Disorder by VA Office of Research and Development — 5 open to participants now, 6 under way, none of them phase 3. Tobacco Use Disorder · VA Office of Research and Development.

Planned enrollment
12th of 16
65 · median 128
Started
2026
with 1 other
No phase
10 of 17
3 open now
Registered
16th of 17
by date

Among the 17 studies in Tobacco Use Disorder by VA Office of Research and Development, this one is the 12th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2026, is one of 10 with no phase, and was the 16th registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

5 of the 17 studies in Tobacco Use Disorder by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Tobacco Use Disorder by VA Office of Research and Development, or all of them as a file.
02

Study summary

Smoking disproportionally impacts Veterans, and VA spends $2.7 billion annually on smoking-related health conditions. Veterans with serious mental illness (SMI) smoke tobacco products at triple the rate of Veterans without any mental illness and die 10-15 years earlier as a result. SMI Veterans who smoke want to quit and FDA-approved tobacco cessation medications are safe, effective, and readily available in VA. However, mental health providers are hesitant to treat smoking and just 11-18% of Veterans with SMI who smoke receive tobacco medication. External facilitation is an effective implementation strategy that can overcome barriers to integrating evidence-based treatment into routine clinical practice. In collaboration with local and operational partners, the proposed CDA-2 will evaluate and refine an external facilitation strategy to improve tobacco medication prescribing in VA SMI clinics. This proposal aligns with VA priorities to enhance timely access to care and improve Veteran outcomes.

Read the detailed description

Tobacco smoking and its health consequences disproportionally impact Veterans. Veterans with serious mental illness (SMI Veterans; schizophrenia spectrum, bipolar spectrum, and other psychotic disorders) have among the highest rates of smoking in VA and die 10-15 years earlier than those without SMI, largely due to smoking-related conditions. Seven FDA-approved tobacco medications are available in VA that are low-cost, safe, and effective for SMI Veterans when combined with brief behavioral counseling: nicotine replacement therapies (lozenge, gum, patch, nasal spray), bupropion, and varenicline. Nearly 70% of SMI Veterans who smoke want to quit, but they are 26% less likely to be prescribed tobacco medication (10.9% vs. 14.3% prescription rate) and also less likely to be advised to quit by physicians. SMI providers face numerous barriers to treating smoking. Implementation activities like external facilitation can address these barriers by coordinating other evidence-based implementation activities, such as academic detailing and auditing with feedback, that are tailored to local needs and show promise for improving tobacco treatment delivery in VA mental health clinics. Despite the availability of tobacco treatment in VA, smoking-related conditions remain the leading cause of death for SMI Veterans and account for nearly 8% of VA health care expenditures: $2.7 billion annually. Using external facilitation and other implementation strategies can help integrate tobacco treatment into routine mental health care and, in turn, reduce a critical health disparity between Veterans with and without SMI and maximize the VA's use of existing resources. The primary purpose of this study is to evaluate the acceptability and feasibility of this multi-component implementation strategy designed to improve tobacco treatment delivery in VAMHCS SMI clinics.

03

Conditions studied

  • Serious Mental Illness
  • Tobacco Use Disorder

Keywords

  • mental health services
  • tobacco use disorder
  • delivery of health care, integrated
  • attitude of health personnel
  • qualitative research
  • implementation science
  • mental disorders
  • Veterans health services
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Providers:

  • VA Maryland Health Care System patient care providers serving Veterans in Critical Time Intervention, Psychosocial Rehabilitation and Recovery Center, Mental Health Integrative Case Management, or outpatient psychiatry clinics

Veterans receiving direct letters:

  • Had an appointment in VA Maryland Health Care System, Critical Time Intervention, Psychosocial Rehabilitation and Recovery Center, Mental Health Integrative Case Management, or outpatient psychiatry clinics in the last 30 days
  • Diagnosed with a serious mental illness
  • Positive tobacco use screen
  • Appointment scheduled with an outpatient psychiatric prescriber in the next 30 days

    • Of note, study staff are not directly recruiting Veterans for this implementation intervention component

Veteran chart review:

  • All Veterans actively enrolled in VAMHCS medical facilities with at least one encounter during a given period with available smoking health factor data

    • Of note, study staff are not directly recruiting Veterans for this data analysis

Exclusion criteria

Exclusion Criteria:

Providers:

  • None

Veterans receiving direct letters:

  • Active prescription for bupropion, varenicline, or any nicotine replacement therapy
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    Multi-component external facilitation

    The facilitation strategy will involve an external facilitator who will support other implementation activities: educational outreach, auditing performance and providing feedback, training, Veteran outreach, champions, and implementation team meetings.

    Other: Multi-component facilitation

Interventions

  • OtherMulti-component facilitation

    Facilitation includes identifying multilevel barriers to change, selecting implementation activities to address known barriers, tailoring implementation activities to the local context, providing social support, problem-solving challenges, conducting administrative duties, and refining implementation activities over time in response to data-driven needs for improvement. Facilitation will support multiple other evidence-based implementation activities like auditing performance with feedback and engaging patients. The proposed study will use an external facilitator - someone outside the clinic with expertise in implementation science and tobacco treatment - to partner with clinic representatives and operational leaders who share a commitment to increasing adoption of tobacco medication.

06

What researchers measure

Primary outcomes

  1. Semi-structured, one-on-one interviews

    Acceptability and feasibility: Interviews will gauge provider satisfaction with the implementation strategy (acceptability) and provider perceptions of the actual fit of the implementation strategy with the clinical setting (feasibility). This qualitative data will be analyzed for common themes. The number of providers endorsing each theme will be quantified.

    Time frame: 12 months after start of implementation at each site

  2. Implementation tracker

    Based on observation, the investigators will track provider attendance at trainings (number of providers attending divided by total number of eligible providers) and number of academic detailing sessions completed per provider (minimum = 1, maximum = 3) in an excel spreadsheet as benchmarks of feasibility to inform refinements to the implementation strategy.

    Time frame: Weekly for the duration of the implementation at each site (12 months)

Other outcomes

  1. Smoking Knowledge, Attitudes, and Practices Scale: Practices subscale only

    Adoption: The survey will inquire about provider frequency of delivering evidence-based tobacco treatment to Veterans. Minimum = 0 (never), maximum = 4 (always). A higher score is desired because it suggests frequent tobacco treatment delivery.

    Time frame: Before implementation, at end of implementation (12 months), and 12 months after end of implementation (24 months)

  2. Prescriptions of tobacco cessation medication

    Reach: Change in the proportion of eligible Veterans prescribed a medication for tobacco use from the VHA corporate data warehouse.

    Time frame: Monthly 12 months before through 12 months after the end of implementation (36 months)

  3. Changes in tobacco use

    Effectiveness: Changes in the proportion of Veterans quitting tobacco from the VHA corporate data warehouse.

    Time frame: Monthly 12 months before through 12 months after the end of implementation (36 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Person-level qualitative data from semi-structured interviews can be provided as a de-identified, anonymized dataset depending on the need of the requester pursuant to a Data Use Agreement appropriately limiting use of the dataset and prohibiting the recipient from identifying, or taking steps to re-identify, any individuals whose data are included in the dataset. Audio recordings of qualitative interviews will not be shared. For chart review data, a Limited Dataset will be created and shared pursuant to a Data Use Agreement appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available for sharing starting 6 months after publication.

Access criteria: Person-level qualitative data from semi-structured interviews can be provided as a de-identified, anonymized dataset depending on the need of the requester pursuant to a Data Use Agreement appropriately limiting use of the dataset and prohibiting the recipient from identifying, or taking steps to re-identify, any individuals whose data are included in the dataset. Audio recordings of qualitative interviews will not be shared. For chart review data, a Limited Dataset will be created and shared pursuant to a Data Use Agreement appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2030, 41 months after the start.

Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 41 months is above that.

Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Oct 2026 → Aug 2026, primary completion Jun 2030 → Jan 2030 and completion Oct 2031 → May 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2026
First posted
Mar 6, 2026
StartActual
Aug 3, 2026was Oct 2026
Primary completionEst.
Jan 31, 2030was Jun 2030
CompletionEst.
May 1, 2031was Oct 2031
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD is now Recruiting
Oct 15, 2026
Start date
Oct 1, 2026→Aug 3, 2026 (actual)
Oct 15, 2026
Primary completion
Jun 30, 2030→Jan 31, 2030
Oct 15, 2026
Study completion
Oct 1, 2031→May 1, 2031
Oct 15, 2026
Contact
Study contact changed: c•••@va.gov · •••7948→F•••@va.gov · •••7000. See the current contact
Oct 15, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD · Baltimore, United StatesContact c•••@va.gov · •••7948→F•••@va.gov · •••7000
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD is now Recruiting
    Start date Oct 1, 2026→Aug 3, 2026 (now actual)
    Primary completion Jun 30, 2030→Jan 31, 2030
    Study completion Oct 1, 2031→May 1, 2031
    Contact Study contact changed: c•••@va.gov · •••7948→F•••@va.gov · •••7000. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD · Baltimore, United StatesContact c•••@va.gov · •••7948→F•••@va.gov · •••7000
    + 4 other changes: verification date, description, conditions and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07455526
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Aug 3, 2026
Primary completion
Jan 31, 2030 (estimated)
Completion
May 1, 2031 (estimated)
Last update
Oct 15, 2026

Study contacts

Corinne N Kacmarek, PhD
Contact
corinne.kacmarek2@va.gov
(410) 340-0727
Frederick M Ivey, PhD
Contact
Frederick.Ivey@va.gov
(410) 605-7000 ext. 56510
Corinne N Kacmarek, PhD
principal investigator · Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion